Lin Yan, Lin Fengkang, Anuchapreeda Songyot, Chaiwongsa Rujirek, Duangmano Suwit, Ran Bing, Pornprasert Sakorn
Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University Chiang Mai 50200, Thailand.
Institute for Cancer Medicine, School of Basic Medical Sciences, Southwest Medical University Luzhou 646000, China.
Am J Transl Res. 2021 Jun 15;13(6):5969-5984. eCollection 2021.
As a type of breast cancer that has relatively strong invasiveness, triple negative breast cancer (TNBC) seriously affects the survival of patients. microRNAs (miRNAs) have been shown to exert a prominent regulatory effect on the disease, among which miR-133b is reported to be involved in the pathological mechanism of breast cancer, but its role in TNBC remains unclear.
In this study, real-time quantitative PCR (RT-qPCR) and Western blotting (WB) were performed for detecting the expressions of miR-133b, fibroblast growth factor receptor 1 (FGFR1), and Wingless/Integrated (Wnt)-β-catenin pathway markers (Wnt1, β-catenin, nuclear-β-catenin, p-GSK-3β, GSK-3β, cyclinD1, and FOXQ1). With TNBC cells and DDP-resistant TNBC cells (TNBC/DDP cells) used as research objects, their proliferation and apoptosis were measured by Cell Counting Kit-8 (CCK-8) assays and Flow cytometry, respectively. Then, the targeted relationship between miR-133b and FGFR1 was verified by Dual luciferase reporter gene assay (DLRGA).
In our study, miR-133b was down-regulated while FGFR1 up-regulated in TNBC. The ectopic expression of miR-133b remarkably inhibited the proliferation and colony formation but induced apoptosis of TNBC cells, and inactivated the Wnt-β-catenin pathway. The knockdown of FGFR1 had similar effects. Additionally, miR-133b targeted and negatively regulated FGFR1. Up-regulating miR-133b or down-regulating FGFR1 could enhance the proliferation and DDP sensitivity of TNBC cells or TNBC/DDP cells. Up-regulating FGFR1 could offset the anti-TNBC cell survival and DDP sensitization shown by ectopic expression of miR-133b.
To sum up, miR-133b can inhibit the growth and DDP resistance of TNBC cells by targeting FGFR1 and inactivating the Wnt-β-catenin pathway.
三阴性乳腺癌(TNBC)作为一种侵袭性相对较强的乳腺癌类型,严重影响患者的生存。微小RNA(miRNA)已被证明对该疾病发挥着显著的调节作用,其中miR-133b据报道参与乳腺癌的病理机制,但其在TNBC中的作用仍不清楚。
在本研究中,采用实时定量聚合酶链反应(RT-qPCR)和蛋白质免疫印迹法(WB)检测miR-133b、成纤维细胞生长因子受体1(FGFR1)以及无翅型/整合型(Wnt)-β-连环蛋白通路标志物(Wnt1、β-连环蛋白、核β-连环蛋白、p-GSK-3β、GSK-3β、细胞周期蛋白D1和FOXQ1)的表达。以TNBC细胞和耐顺铂TNBC细胞(TNBC/DDP细胞)作为研究对象,分别通过细胞计数试剂盒-8(CCK-8)法和流式细胞术检测它们的增殖和凋亡情况。然后,通过双荧光素酶报告基因检测(DLRGA)验证miR-133b与FGFR1之间的靶向关系。
在我们的研究中,TNBC中miR-133b表达下调而FGFR1表达上调。miR-133b的异位表达显著抑制TNBC细胞的增殖和集落形成,但诱导其凋亡,并使Wnt-β-连环蛋白通路失活。敲低FGFR1也有类似的效果。此外,miR-133b靶向并负调控FGFR1。上调miR-133b或下调FGFR1可增强TNBC细胞或TNBC/DDP细胞的增殖及对顺铂的敏感性。上调FGFR1可抵消miR-133b异位表达所显示的抗TNBC细胞存活及顺铂致敏作用。
综上所述,miR-133b可通过靶向FGFR1并使Wnt-β-连环蛋白通路失活来抑制TNBC细胞的生长和顺铂耐药性。